Product Description
NA-931, based on the mechanism of action of four receptor agonists—IGF-1, GLP-1, GIP, and Glucagon—and their roles to facilitate weight loss without many of the adverse events associated with current obesity drugs. NA-931 is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments. In the quadruple mechanism of action of NA-931, Insulin-like Growth Factor 1 (IGF-1) plays a pivotal role in fuel metabolism and regulation of body composition. Additionally, IGF-1 in conjunction with GLP‐1, and GIP have been shown to be effective for weight loss in non-diabetic patients with obesity when given as adjunctive therapy to diet and exercise. IGF-1 also contributes to modulating glucagon secretion by inhibiting the ability of low glucose concentration to stimulate glucagon expression and secretion. (Sourced from: https://www.biomedind.com/NA-931.html)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NeuroActiva
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|